Xstrahl took part in the 63rd Annual Meeting of the Radiation Research Society held in Cancun, Mexico, on 15th to 18th October. The event, which gathered together most eminent professionals in the radiation research field, had an outstanding scientific program...
November 9th, 2017 – Following the supply of an Xstrahl 200 to the Island of Cuba, Xstrahl Medical has reached out to the rest of South America and Spanish speaking countries to solve the ever-present problem of skin cancer. Whilst pale skin is at a higher risk of...
Patients with glioblastoma have poor outcomes due to local relapse despite surgery and high-dose radiotherapy. Resistance to radiotherapy is thought to be due to efficiency of DNA repair cells, such as RAD51, are able to survive DNA damage from radiotherapy and...
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in children. Despite intensive research in recent decades the prognosis for patients with metastatic or relapsed diseases has only marginally improved. New therapeutic concepts in anti-tumor therapy aim...
The Xstrahl 100 is perfectly suited for the treatment of non-melanoma skin cancers, and with Australia recording skin cancer rates of 2 in every 3 adults, the need for an effective and versatile treatment method is essential. With the aim to offer non-melanoma skin...
October 17th, 2017 – The new Xstrahl RADiant System has been granted FDA 510(k) clearance for sale in the US. The RADiant System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and...
Radiation induced normal tissue damage and toxicity is sometimes an inevitable side effect when treating tumors with radiation therapy. Despite the technological advancements in imaging, treatment planning, and dose delivery, radiation exposure to organs and tissues...
In the present study, we address the important issue of whether B-cells protected from irradiation-induced cell death, may survive with elevated levels of DNA damage. If so, such cells would be at higher risk of gaining mutations and undergoing malignant...
Xstrahl attended the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) conference in San Diego, this September, the world's largest meeting for the radiation oncology community. Over a fantastic four days Xstrahl Life Sciences and Medical...